Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study

2015 ◽  
Vol 46 (6) ◽  
pp. 521-528 ◽  
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Kojiro Michitaka ◽  
Hidenori Toyoda ◽  
Toshifumi Tada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interventional Radiology ◽  
Liver Cirrhosis ◽  
Multicenter Study ◽  
Survival Benefit

scholarly journals Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Liver Cancer ◽  
2016 ◽  
Vol 5 (3) ◽  
pp. 175-189 ◽  
Author(s):  
Satoshi Kitai ◽  
Masatoshi Kudo ◽  
Naoshi Nishida ◽  
Namiki Izumi ◽  
Michiie Sakamoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Survival Benefit ◽  
Locoregional Treatment ◽  
Advanced Liver Cirrhosis

scholarly journals Reuse of a Pediatric Liver Graft: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-2 ◽  
Author(s):  
Koray Karabulut ◽  
Cengiz Eris ◽  
Turgut Piskin ◽  
Cuneyt Kayaalp ◽  
Sezai Yilmaz
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interventional Radiology ◽  
Liver Cirrhosis ◽  
Abdominal Pain ◽  
Brain Death ◽  
Acute Abdominal Pain ◽  
Multiorgan Failure ◽  
Liver Graft ◽  
Liver Donor ◽  
Artery Thrombosis

We report the reuse of a liver graft after brain death of the first recipient. The liver donor was an 8-year-old male who died as a result of head injury. The graft was implanted first to a 4-year-old girl for fulminant hepatic failure. Unfortunately she developed progressive coma and brain death on fifth day of transplantation. The graft functions were normal, and reuse of the liver graft was planned. After informed consent, the graft was transplanted to a 31-year-old female recipient who has hepatocellular carcinoma with an underlying cryptogenic liver cirrhosis. The patient was discharged to home on 9th day after an uneventful postoperative period. However, she was readmitted to hospital with an acute abdominal pain 30 days after the operation. Hepatic artery thrombosis was diagnosed, and the attempt to open the artery by interventional radiology was unsuccessful. She died of sepsis and multiorgan failure on 37th posttransplant day.

Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis

2018 ◽  
Vol 36 (4) ◽  
pp. 314-321 ◽  
Author(s):  
Kazuto Tajiri ◽  
Yoshiharu Tokimitsu ◽  
Hiroyuki Ito ◽  
Yoshinari Atarashi ◽  
Kengo Kawai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Renal Function ◽  
Body Weight ◽  
Multivariate Analysis ◽  
Liver Cirrhosis ◽  
Survival Benefit ◽  
Refractory Ascites ◽  
Body Weight Change ◽  
Decompensated Liver Cirrhosis ◽  
Advanced Cirrhosis

Aims: The study aimed to evaluate the effects of tolvaptan treatment on survival of patients with decompensated liver cirrhosis with refractory ascites. Methods: This multicenter, retrospective, observational study included patients with cirrhosis who were treated with tolvaptan for hepatic ascites refractory to conventional diuretics. Patients who could and could not decrease accompanying diuretics within 1 month after tolvaptan administration were defined as the “Decreased” and “Not-decreased” groups, respectively. Results: Median body weight change 1 week after tolvaptan treatment was –1.95 kg, with the 50% of patients experiencing a 2 kg/week reduction. Spot urinary sodium was found to be a better predictor of tolvaptan response than liver function and liver fibrosis markers. Median survival was significantly longer (not reached versus 116 days, p = 0.005) and serum creatinine concentrations 12 weeks after tolvaptan administration significantly lower (0.99 vs. 1.55 mg/dL, p < 0.05) in the Decreased than in the Not-decreased group. Multivariate analysis showed that the presence of viable hepatocellular carcinoma (hazards ratio [HR] 2.14, p = 0.02) and a decrease in diuretics were independently prognostic of survival (HR 0.36, p < 0.01). Conclusions: The maintenance of renal function is essential in enhancing survival of patients with cirrhosis. Doses of diuretics should be adjusted appropriately during tolvaptan treatment.

Sign in / Sign up

Export Citation Format

Share Document